IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

July 2019

IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer.

Read the press release here (in swedish)

Abstract shows the value of UBC Rapid

An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer.

Meet IDL Biotech at Coalition against Typhoid Fever

Every two years, the Coalition against Typhoid, based at the Sabin Vaccine Institute (Sabin), convenes the International Conference on Typhoid and Other Invasive Salmonelloses. The 11th International Conference on Typhoid and Other Invasive Salmonelloses will be held from March 26-28, 2019 in Hanoi, Vietnam. IDL Biotech is proud to be a sponsor of this important conference.

IDL Biotech

Skip this intro